HRP20210749T1 - Farmaceutski pripravci koji sadrže azd9291 - Google Patents
Farmaceutski pripravci koji sadrže azd9291 Download PDFInfo
- Publication number
- HRP20210749T1 HRP20210749T1 HRP20210749TT HRP20210749T HRP20210749T1 HR P20210749 T1 HRP20210749 T1 HR P20210749T1 HR P20210749T T HRP20210749T T HR P20210749TT HR P20210749 T HRP20210749 T HR P20210749T HR P20210749 T1 HRP20210749 T1 HR P20210749T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical
- parts
- pharmaceutical preparation
- preparation according
- diluents
- Prior art date
Links
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 229960003278 osimertinib Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 22
- 239000008024 pharmaceutical diluent Substances 0.000 claims 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 6
- 239000000449 pharmaceutical disintegrant Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229920001100 Polydextrose Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 229940081735 acetylcellulose Drugs 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical class CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical class OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 229960002737 fructose Drugs 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 229960002160 maltose Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- FUKSNUHSJBTCFJ-UHFFFAOYSA-N osimertinib mesylate Chemical compound CS(O)(=O)=O.COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 FUKSNUHSJBTCFJ-UHFFFAOYSA-N 0.000 claims 1
- 239000001259 polydextrose Substances 0.000 claims 1
- 235000013856 polydextrose Nutrition 0.000 claims 1
- 229940035035 polydextrose Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940083037 simethicone Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (18)
1. Farmaceutski pripravak koji sadrži:
(a) od 2 do 70 dijelova Sredstva;
(b) od 5 do 96 dijelova dva ili više farmaceutskih razrjeđivača;
(c) od 2 do 15 dijelova jednog ili više farmaceutskih sredstava za raspadanje;
(d) od 0 do 0,75 dijelova jednog ili više farmaceutskih sredstava za topivost; i
(e) od 0,5 do 3 dijela jednog ili više farmaceutskih sredstava za povećanje skliskosti;
pri čemu svi dijelovi su maseni i zbroj dijelova (a)+(b)+(c)+(d)+(e)=100; pri čemu je jedan od dva ili više farmaceutskih razrjeđivača mikrokristalna celuloza pri čemu mikrokristalna celuloza čini od 7 do 30 mas.% dva ili više farmaceutskih razrjeđivača (b); i pri čemu je Sredstvo N-(2-{2-dimetilaminoetil-metilamino}-4-metoksi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamid ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak prema zahtjevu 1 naznačen time što farmaceutski pripravak sadrži od 1 do 2,5 dijela jednog ili više farmaceutskih sredstava za povećanje skliskosti (e).
3. Farmaceutski pripravak prema zahtjevu 1 ili zahtjevu 2 naznačen time što jedno ili više farmaceutskih sredstava za povećanje skliskosti (e) sadrži natrijev stearil fumarat i/ili jedan ili više behenatnih estera glicerina.
4. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što farmaceutski pripravak sadrži od 2 do 10 dijelova jednog ili više farmaceutskih sredstava za raspadanje (c).
5. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 4 naznačen time što jedno ili više farmaceutskih sredstava za raspadanje (c) sadrži nisko supstituiranu hidroksipropil celulozu.
6. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što farmaceutski pripravak sadrži od 0 do 0,25 dijelova jednog ili više farmaceutskih sredstava za topivost (d).
7. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što farmaceutsko sredstvo za topivost (d) nije prisutno.
8. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što farmaceutski pripravak sadrži od 5 do 50 dijelova Sredstva (a).
9. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što farmaceutski pripravak sadrži od 7 do 30 dijelova Sredstva (a).
10. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 9 naznačen time što je Sredstvo mezilatna sol N-(2-{2-dimetilaminoetil-metilamino}-4-metoksi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida.
11. Farmaceutski pripravak prema zahtjevu 1 naznačen time što sadrži:
(a) od 5 do 50 dijelova Sredstva;
(b) od 5 do 96 dijelova dva ili više farmaceutskih razrjeđivača;
(c) od 2 do 15 dijelova jednog ili više farmaceutskih sredstava za raspadanje;
(d) od 0 do 0,75 dijelova jednog ili više farmaceutskih sredstava za topivost; i
(e) od 0,5 do 3 dijela jednog ili više farmaceutskih sredstava za povećanje skliskosti;
pri čemu svi dijelovi su maseni i zbroj dijelova (a)+(b)+(c)+(d)+(e)=100; pri čemu je jedan od dva ili više farmaceutskih razrjeđivača mikrokristalna celuloza pri čemu mikrokristalna celuloza čini od 7 do 30 mas.% dva ili više farmaceutskih razrjeđivača (b) i pri čemu osim mikrokristalne celuloze, drugi farmaceutski razrjeđivač(i) unutar dva ili više farmaceutskih razrjeđivača je/su odabrani od celuloznog acetata, eritritola, etilceluloze, fruktoze, inulina, izomalta, laktitola, laktoze, maltitola, maltodekstrina, maltoze, manitola, polidekstroze, polietilen glikola, pululana, simetikona, natrijevog klorida, sorbitola, škroba, saharoze, trehaloze i ksilitola; i pri čemu jedno ili više farmaceutskih sredstava za raspadanje (c) sadrži nisko supstituiranu hidroksipropil celulozu i pri čemu jedno ili više farmaceutskih sredstava za povećanje skliskosti (e) sadrži natrijev stearil fumarat i/ili jedan ili više behenatnih estera glicerina; i pri čemu je Sredstvo mezilatna sol N-(2-{2-dimetilaminoetil-metilamino}-4-metoksi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida.
12. Farmaceutski pripravak prema zahtjevu 1, naznačen time što je farmaceutski pripravak jezgra tablete koja se sastoji od:
(i) 19,07 mas.% mezilatne soli N-(2-{2-dimetilaminoetil-metilamino}-4-metoksi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida;
(ii) 58,93 mas.% manitola;
(iii) 15,00 mas.% mikrokristalne celuloze;
(iv) 5,000 mas.% nisko supstituirane hidroksipropil celuloze; i
(v) 2,00 mas.% natrijevog stearil fumarata.
13. Farmaceutski pripravak, prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je za uporabu kao lijek.
14. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 13, naznačen time što je uporaba za liječenje karcinoma.
15. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, naznačen time što rak je rak pluća ne-malih stanica
16. Farmaceutska tableta, naznačena time što sadrži farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 12.
17. Farmaceutska tableta koja sadrži jezgru tablete, pri čemu jezgra tablete sadrži farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 12, naznačena time što jezgra tablete ima premaz.
18. Farmaceutska tableta prema zahtjevu 16 ili zahtjevu 17, naznačena time što se koristi u liječenju karcinoma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
| EP15700082.9A EP3089741B1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| PCT/GB2015/050001 WO2015101791A1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210749T1 true HRP20210749T1 (hr) | 2021-06-25 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210749TT HRP20210749T1 (hr) | 2014-01-02 | 2021-05-12 | Farmaceutski pripravci koji sadrže azd9291 |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US10183020B2 (hr) |
| EP (1) | EP3089741B1 (hr) |
| JP (1) | JP6588915B2 (hr) |
| KR (1) | KR102336378B1 (hr) |
| CN (2) | CN114712362A (hr) |
| AR (1) | AR098989A1 (hr) |
| AU (1) | AU2015204218B2 (hr) |
| CA (1) | CA2933403C (hr) |
| CL (1) | CL2016001609A1 (hr) |
| CR (1) | CR20160310A (hr) |
| CY (1) | CY1124848T1 (hr) |
| DK (1) | DK3089741T3 (hr) |
| DO (1) | DOP2016000156A (hr) |
| EA (1) | EA034243B9 (hr) |
| ES (1) | ES2873226T3 (hr) |
| GB (1) | GB201400034D0 (hr) |
| GT (1) | GT201600142A (hr) |
| HK (1) | HK1225655A1 (hr) |
| HR (1) | HRP20210749T1 (hr) |
| HU (1) | HUE054344T2 (hr) |
| IL (1) | IL246186B (hr) |
| LT (1) | LT3089741T (hr) |
| MX (1) | MX367358B (hr) |
| MY (1) | MY183536A (hr) |
| NI (1) | NI201600098A (hr) |
| NZ (1) | NZ721298A (hr) |
| PE (1) | PE20161170A1 (hr) |
| PH (1) | PH12016501310A1 (hr) |
| PL (1) | PL3089741T3 (hr) |
| PT (1) | PT3089741T (hr) |
| RS (1) | RS61927B1 (hr) |
| SG (1) | SG11201605339QA (hr) |
| SI (1) | SI3089741T1 (hr) |
| TW (1) | TWI702953B (hr) |
| UY (1) | UY35933A (hr) |
| WO (1) | WO2015101791A1 (hr) |
| ZA (1) | ZA201605300B (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| KR102444835B1 (ko) | 2016-05-26 | 2022-09-19 | 리커리엄 아이피 홀딩스, 엘엘씨 | Egfr 억제제 화합물 |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| CN110013468B (zh) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | 一种azd9291氘代衍生物药物制剂 |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| MA51823A (fr) | 2018-02-12 | 2021-05-19 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
| EP3758708A1 (en) * | 2018-03-01 | 2021-01-06 | AstraZeneca AB | Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| KR102511672B1 (ko) | 2018-03-23 | 2023-03-17 | 우시 상량 바이오테크놀로지 씨오., 엘티디. | 의약 조성물, 그 제조방법 및 사용 |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| EA202192552A1 (ru) | 2019-03-29 | 2021-12-17 | Астразенека Аб | Осимертиниб для применения в лечении немелкоклеточного рака легкого |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20230056604A1 (en) | 2020-01-20 | 2023-02-23 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical preparations containing iftroban and methods for their preparation |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| EP1480679B1 (en) | 2002-02-26 | 2007-05-23 | Astrazeneca AB | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| JP2008515786A (ja) * | 2004-10-05 | 2008-05-15 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | プロトンポンプアンタゴニスト用の経口医薬調剤 |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| AU2007213028C1 (en) * | 2006-02-09 | 2011-05-19 | Daiichi Sankyo Company, Limited | Anti-cancer pharmaceutical composition |
| JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
| JP2010533205A (ja) * | 2007-07-12 | 2010-10-21 | トラガラ ファーマシューティカルズ，インク． | 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物 |
| WO2012139736A1 (en) | 2011-04-11 | 2012-10-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| ES2900230T3 (es) * | 2011-07-27 | 2022-03-16 | Astrazeneca Ab | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina |
| WO2013105894A1 (en) * | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 AR ARP140104947A patent/AR098989A1/es not_active Application Discontinuation
- 2014-12-29 UY UY0001035933A patent/UY35933A/es not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/zh active
-
2015
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/lt unknown
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/ko active IP Right Grant
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/zh active Pending
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en active Application Filing
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 EA EA201691242A patent/EA034243B9/ru not_active IP Right Cessation
- 2015-01-02 ES ES15700082T patent/ES2873226T3/es active Active
- 2015-01-02 PL PL15700082T patent/PL3089741T3/pl unknown
- 2015-01-02 MX MX2016008744A patent/MX367358B/es active IP Right Grant
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
- 2015-01-02 PT PT157000829T patent/PT3089741T/pt unknown
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 CR CR20160310A patent/CR20160310A/es unknown
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/ja active Active
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/es unknown
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/da active
- 2015-01-02 SI SI201531610T patent/SI3089741T1/sl unknown
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 RS RS20210698A patent/RS61927B1/sr unknown
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/zh active Active
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/hu unknown
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/es unknown
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/es unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/es unknown
- 2016-06-30 PH PH12016501310A patent/PH12016501310A1/en unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/es unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
- 2016-12-14 HK HK16114195A patent/HK1225655A1/zh unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-05-12 HR HRP20210749TT patent/HRP20210749T1/hr unknown
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/el unknown
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| HRP20210529T1 (hr) | Inhibitori za mk2 i njihove uporabe | |
| JP2015078230A5 (hr) | ||
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| JP2014218522A5 (hr) | ||
| MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20171977T1 (hr) | Derivati dolastatina 10 i auristatina | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20191892T1 (hr) | Sublingvalna formulacija riluzola | |
| JP2015523407A5 (hr) | ||
| EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| JP2017516848A5 (hr) | ||
| HRP20211107T1 (hr) | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava | |
| JP2018532806A5 (hr) | ||
| PE20171061A1 (es) | Composiciones farmaceuticas de accion prolongada para hepatitis c | |
| JP2016537344A5 (hr) | ||
| HRP20171514T1 (hr) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt |